Rein Therapeutics (NASDAQ:RNTX) Stock Price Down 0.8% – Time to Sell?

Rein Therapeutics Inc. (NASDAQ:RNTX)’s share price traded down 0.8% on Thursday . The company traded as low as $1.22 and last traded at $1.22. 52,502 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 237,899 shares. The stock had previously closed at $1.23.

Wall Street Analysts Forecast Growth

Several research firms have commented on RNTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen lowered Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Loop Capital set a $6.00 price target on Rein Therapeutics in a research report on Monday, November 3rd. Brookline Capital Management raised Rein Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 3rd. Finally, HC Wainwright began coverage on shares of Rein Therapeutics in a research note on Monday, September 22nd. They set a “buy” rating and a $10.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Rein Therapeutics Stock Down 4.1%

The stock has a 50-day moving average of $1.38 and a 200 day moving average of $1.33. The stock has a market cap of $30.76 million, a PE ratio of -0.44 and a beta of 1.31.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Research analysts forecast that Rein Therapeutics Inc. will post -1.56 EPS for the current fiscal year.

Insider Buying and Selling at Rein Therapeutics

In other news, major shareholder Voss Capital, Lp purchased 104,183 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was acquired at an average price of $1.22 per share, for a total transaction of $127,103.26. Following the acquisition, the insider directly owned 926,441 shares of the company’s stock, valued at approximately $1,130,258.02. This represents a 12.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have purchased 410,233 shares of company stock valued at $550,563. Corporate insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Rein Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Blair William & Co. IL purchased a new position in shares of Rein Therapeutics during the 2nd quarter worth approximately $33,000. Chicago Partners Investment Group LLC acquired a new position in Rein Therapeutics during the second quarter worth $64,000. Exencial Wealth Advisors LLC purchased a new position in shares of Rein Therapeutics during the second quarter worth $43,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Rein Therapeutics in the second quarter valued at $716,000. Finally, Sigma Planning Corp purchased a new stake in shares of Rein Therapeutics in the 2nd quarter valued at $387,000. 90.89% of the stock is owned by hedge funds and other institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.